Please assess the completion status of the following clinical trial:

Trial Title: Naltrexone in Borderline Personality Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* In- and Outpatients:Borderline personality disorder according to the Diagnostic and Statistical Manual for Mental Disorders, 4.Edition (DSM IV)~* DES-(Dissociative Experience Scale)-score: \> or equal 18 according to amendment4 (former value according to amendment 2 was \> or equal 25).~* Urinary test of opiates negative~* No psychopharmacological treatment for two weeks prior to study (fluoxetine four weeks)~* No Lithium for two months~Exclusion Criteria:~* Lifetime diagnosis of psychotic disorder~* Current major depressive disorder (MDD)~* Lifetime diagnosis opioid dependence or current opioid abuse (10 to 7 days prior to study)~* Comedication with opioid analgetics~* Known naltrexone intolerance~* Liver disease~* Pregnancy and lactation period~* Other severe medical or neurological diseases~* Simultaneous participation in another study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Blinded sequential administration: naltrexon 50 mg (3 weeks)- placebo (3 weeks)- placebo (1 week)
- 2 (Type: OTHER): Blinded sequential administration: 200mg naltrexone (3 weeks) - placebo (3 weeks)- placebo (1 week)
- 3 (Type: OTHER): Blinded sequential administration: placebo (3 weeks) - 200mg naltrexone (3 weeks) - placebo (1 week)
- 4 (Type: OTHER): Blinded sequential administration: placebo (3 weeks) - 50mg naltrexone (3 weeks) - placebo (1 week)

Based on this trial design, predict the completion outcome and termination type (if applicable).